Nasdaq:US$18.88 (+0.85) | HKEX:HK$29.95 (+0.65) | AIM:£2.97 (-0.03)
Search
Announcements
1234567
8
9101112131415
found Documents: 720
Announcements & Press Releases, Group, Press Releases | 11 May 2018

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference
Press Release   London: Friday, May 11, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2018 Health Care Confe
Read More
Announcements & Press Releases, Regulatory Notice | 30 Apr 2018

Total Voting Rights
London: Monday, April 30, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 30, 2018, the issued share capital of Chi-Med consisted of 66,484,620 ordinary sh
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 27 Apr 2018

Results of AGM Meeting
London: Friday, April 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2018 were duly pa
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Apr 2018

Block Admission
London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,425,597 ordinary shares, par value of US$
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Apr 2018

Grant of Share Options under Share Option Scheme
London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on April 20, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Mar 2018

Total Voting Rights
London: Thursday, March 29, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 29, 2018, the issued share capital of Chi-Med consisted of 66,476,279 ordinary
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Mar 2018

Vesting of awards under the Long Term Incentive Plan
London: Wednesday, March 28, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2017 annual report of Chi-Med on March 26, 2018, the following awards granted under the Long Term In
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 26 Mar 2018

2017 Annual Report and Notice of Annual General Meeting
London: Monday, March 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Mar 2018

Director’s Share Dealing
London: Wednesday, March 21, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Graeme Jack, Independent Non-executive Director, purchased a total of 3,000 American Depositary Shar
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 20 Mar 2018

Grant of Share Options under Share Option Scheme
London: Tuesday, March 20, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 19, 2018, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 19 Mar 2018

Director's Share Dealing
London: Monday, March 19, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company (“ADSs”,
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 12 Mar 2018

Publication of Form 20-F for the Year Ended December 31, 2017
View Form 20-F (PDF)
Announcements & Press Releases, Group | 12 Mar 2018

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results in line with guidance Group revenue up 12% to $
Read More
View Full Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 6 Mar 2018

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China
London: Tuesday, March 6, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor (“EGFR”) gene amplifi
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Feb 2018

Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer
London: Tuesday, February 13, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer (“NSC
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 5 Feb 2018

Chi-Med to Announce 2017 Final Results
London: Monday, February 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT). An analy
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Dec 2017

Total Voting Rights
London: Friday, December 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 29, 2017, the issued share capital of Chi-Med consisted of 66,447,037 ordin
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Dec 2017

Blocklisting Six Monthly Return
London: Friday, December 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: H
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 15 Dec 2017

Chi-Med Initiates Fruquintinib U.S. Clinical Trials
London: Friday, December 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent oral inhibitor of vas
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Nov 2017

TR-1: Notification of major interest in shares
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Nov 2017

TR-1: Notification of major interest in shares
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 31 Oct 2017

Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer
London: Tuesday, October 31, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has initiated FRUTIGA, a pivotal Phase III clinical trial of fruquintinib in combination with paclitaxel (Taxol®) for the treatment in advanced g
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 30 Oct 2017

Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market
London: Monday, October 30, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the closing of its underwritten public offering of American Depositary Shares ("ADSs") on the Nasdaq Global Select Market, previously
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 27 Oct 2017

Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Friday, October 27, 2017: Hutchison China MediTech L
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 26 Oct 2017

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Wednesday, October 25, 2017: Hutchison China MediTec
Read More
Download Announcement (PDF)
Group, Press Releases | 26 Oct 2017

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market
London: Wednesday, October 25, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the pricing of the underwritten public offering previously announced by Chi-Med on October 24, 2017. Chi-Med will issue and sell 9
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 25 Oct 2017

Chi-Med Announces Proposed Offering of ADSs (RNS)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Tuesday, October 24, 2017: Hutchison China MediTech
Read More
Download Full Announcement (PDF, 87 pages including Appendix)
Group, Press Releases | 24 Oct 2017

Chi-Med Announces Proposed Offering of ADSs
London: Tuesday, October 24, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares (“ADSs”), each
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 19 Oct 2017

TR-1: Notification of major interest in shares
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Oct 2017

Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification
– Data for savolitinib in combination with Tagrisso® or Iressa® presented at World Conference on Lung Cancer –  – New data give insights into disease progression and potential next-generation treatment strategies in patients with EGFR-muta
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 16 Oct 2017

Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer
Press Release – Fruquintinib in combination with Iressa® (gefitinib) shows promising efficacy and an acceptable safety profile – – Further validation of strong potential for use of fruquintinib in combination with other cancer therapies du
Read More
Downoad Press Release (PDF)
Announcements & Press Releases, Group, Press Releases | 12 Oct 2017

Chi-Med Appoints Professor Tony Mok to Board of Directors
Appointment of Director London: Thursday, October 12, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of t
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Sep 2017

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting
Press Release   – Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib – – Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Sep 2017

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting
Press Release – Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa® and Tagrisso® refractory patients with MET amplification – – Results to further validate Chi-Med’s scientific strategy of designing highly
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Sep 2017

Total Voting Rights
London: Friday, September 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 29, 2017, the issued share capital of Chi-Med consisted of 60,750,132 ord
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Aug 2017

Director's Share Dealing
London: Thursday, August 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated with Mr To,
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Aug 2017

Chi‑Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL‑689 in Lymphoma Patients in China
Press Release London: Tuesday, August 29, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has initiated a Phase I clinical trial of HMPL‑689 in China. HMPL-689 is a novel, highly selective and potent small molecule inhib
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 22 Aug 2017

Director's Share Dealing
London: Tuesday, August 22, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 4,000 American Depositary Shares of
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 18 Aug 2017

Directors' Share Dealing
London: Friday, August 18, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited (“WCL”), a person closely
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 15 Aug 2017

Directors' Share Dealing
London: Tuesday, August 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 10 Aug 2017

Director’s Share Dealing
London: Thursday, August 10, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of th
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 7 Aug 2017

Directors' Share Dealing
London: Monday, August 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“P
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 31 Jul 2017

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs
London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2017

Total Voting Rights
London: Friday, June 30, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 30, 2017, the issued share capital of Chi-Med consisted of 60,737,204 ordinary shar
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Jun 2017

Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma
AstraZeneca PLC (“AstraZeneca”) (LON/STO/NYSE: AZN) Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM)   London: Thursday, June 29, 2017: Chi-Med and AstraZeneca today announce that they have initiated
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Jun 2017

Blocklisting Six Monthly Return
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limited 2. Name of sc
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group, Press Releases | 29 Jun 2017

Chi-Med to Announce 2017 Half-Year Financial Results
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST). An ana
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 22 Jun 2017

Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China
Press Release London: Thursday, June 22, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL‑453 in China.  HMPL‑453 is a novel, highly selective and potent small mol
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 16 Jun 2017

Director’s Share Dealing
London: Friday, June 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Dynamic Drive Limited, a person closely associated (“PCA”) with Mr Simon To, Executive Director and Chairma
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 12 Jun 2017

Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer
– Application accepted by CFDA for technical review by the Center for Drug Evaluation – – Triggers RMB30.8 million milestone payment from Eli Lilly and Company (“Lilly”) – London: Monday, June  12, 2017: Hutchison China MediTech L
Read More
Download Announcement (PDF)
1234567
8
9101112131415